- Israel's Compugen ( NASDAQ: CGEN ) said it expects to receive a milestone payment of $7.5M from AstraZeneca as the British drugmaker dosed the first patient in its phase 2 trial of anti-tumor drug AZD2936.
- The phase 2 study, dubbed ARTEMIDE, is evaluating AZD2936, a PD-1/TIGIT bispecific antibody derived from Compugen's clinical-stage anti-TIGIT antibody COM902.
- "Like COM902, AZD2936 was engineered to reduce Fc effector functionality, with the potential to enhance anti-tumor activity," said Compugen President, and CEO Anat Cohen-Dayag.
- The companies entered an agreement in 2018 granting AstraZeneca an exclusive license to use certain Compugen's monospecific antibodies.
For further details see:
Compugen to get $7.5M milestone as AstraZeneca begins dosing in cancer drug study